PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$410M
AUM Growth
+$106M
(+35%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
62.72%
Holding
47
New
9
Increased
19
Reduced
10
Closed
8
Avg Time Held
1.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$42M |
| 2 |
Amicus Therapeutics
FOLD
|
+$13.6M |
| 3 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$12.3M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$9.21M |
| 5 |
Biohaven
BHVN
|
+$7.83M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schrodinger
SDGR
|
+$7.6M |
| 2 |
Intuitive Surgical
ISRG
|
+$6.93M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$6.38M |
| 4 |
AbCellera Biologics
ABCL
|
+$6.28M |
| 5 |
BridgeBio Pharma
BBIO
|
+$4.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $49.6M | 12.11% |
1,773,649
+458,751
| +35% | +$12.3M |
2021 Q1
17 quarters
|
|
|
2
UnitedHealth
UNH
$355B
| $34.3M | 8.37% |
+110,000
| New | +$42M |
2025 Q2
0 quarters
|
|
3
MeiraGTx Holdings
MGTX
$904M
| $29.9M | 7.29% |
4,587,423
+895,877
| +24% | +$5.29M |
2022 Q1
13 quarters
|
|
4
ADC Therapeutics
ADCT
$185M
| $28.1M | 6.84% |
10,467,771
+924,767
| +10% | +$1.95M |
2022 Q3
11 quarters
|
|
|
5
BridgeBio Pharma
BBIO
$12.7B
| $20.4M | 4.98% |
472,687
-137,313
| -23% | -$4.99M |
2024 Q1
5 quarters
|
|
6
Roivant Sciences
ROIV
$24.3B
| $20.4M | 4.97% |
1,808,539
-17,624
| -1% | -$191K |
2024 Q1
5 quarters
|
|
|
7
DELISTED
Amicus Therapeutics
FOLD
| $19.9M | 4.86% |
3,480,044
+2,100,661
| +152% | +$13.6M |
2024 Q4
2 quarters
|
|
8
Janux Therapeutics
JANX
$1.05B
| $19.7M | 4.81% |
853,904
+164,003
| +24% | +$4.32M |
2024 Q3
3 quarters
|
|
9
Kura Oncology
KURA
$855M
| $18.4M | 4.48% |
3,181,184
+1,102,869
| +53% | +$6.76M |
2023 Q2
8 quarters
|
|
10
Zymeworks
ZYME
$1.78B
| $16.4M | 4.01% |
1,309,904
+352,675
| +37% | +$4.2M |
2024 Q1
5 quarters
|
|
11
Icon
ICLR
$13B
| $14.3M | 3.5% |
98,558
+38,459
| +64% | +$5.45M |
2024 Q4
2 quarters
|
|
12
argenx
ARGX
$51.5B
| $12.1M | 2.96% |
22,000
+8,300
| +61% | +$4.82M |
2025 Q1
1 quarter
|
|
|
13
Mirum Pharmaceuticals
MIRM
$5.19B
| $10.2M | 2.48% |
200,000
-143,326
| -42% | -$6.38M |
2022 Q1
13 quarters
|
|
14
Syndax Pharmaceuticals
SNDX
$1.21B
| $10.1M | 2.47% |
1,079,673
+470,421
| +77% | +$5.18M |
2024 Q2
4 quarters
|
|
15
Tectonic Therapeutic
TECX
$410M
| $8.78M | 2.14% |
442,056
+43,171
| +11% | +$875K |
2025 Q1
1 quarter
|
|
|
16
DELISTED
Crinetics Pharmaceuticals
CRNX
| $8.57M | 2.09% |
+298,123
| New | +$9.21M |
2025 Q2
0 quarters
|
|
17
CytomX Therapeutics
CTMX
$486M
| $7.98M | 1.95% |
3,517,113
-412,895
| -11% | -$666K |
2024 Q3
3 quarters
|
|
18
Immunovant
IMVT
$5.76B
| $7.67M | 1.87% |
479,400
+119,400
| +33% | +$1.81M |
2024 Q1
5 quarters
|
|
|
19
Biohaven
BHVN
$1.65B
| $7.61M | 1.85% |
539,071
+439,071
| +439% | +$7.83M |
2025 Q1
1 quarter
|
|
20
Concentra Group Holdings
CON
$4.78B
| $6.42M | 1.57% |
+312,105
| New | +$6.67M |
2025 Q2
0 quarters
|
|
21
LivaNova
LIVN
$4.19B
| $6.3M | 1.54% |
140,000
+12,700
| +10% | +$524K |
2024 Q3
3 quarters
|
|
22
DexCom
DXCM
$31.5B
| $6.11M | 1.49% |
+70,000
| New | +$5.49M |
2025 Q2
0 quarters
|
|
23
CareDx
CDNA
$3.35B
| $5.92M | 1.44% |
302,808
+166,215
| +122% | +$2.95M |
2024 Q4
2 quarters
|
|
24
DELISTED
Select Medical
SEM
| $5.37M | 1.31% |
+353,820
| New | +$5.52M |
2025 Q2
0 quarters
|
|
25
Shattuck Labs
STTK
$535M
| $5.26M | 1.28% |
6,638,935
| – | – |
2021 Q3
15 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2025 Portfolio in Review
As of Q2 2025, Prosight Management held 47 positions worth $410M, up 35% from $304M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management deployed $109M of net new capital in Q2 2025, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 110,000 shares worth $34.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $6.38M trimmed.
- Prosight Management's largest Q2 2025 buy was UnitedHealth: 110,000 shares worth $34.3M.
- Prosight Management added most to Amicus Therapeutics in Q2 2025, an estimated $13.6M increase.
- Prosight Management's biggest Q2 2025 reduction was Mirum Pharmaceuticals, cutting an estimated $6.38M.
- Prosight Management fully exited Schrodinger in Q2 2025, selling an estimated $7.6M.
- Prosight Management's ten largest holdings make up 63% of its $410M portfolio in Q2 2025.
- Prosight Management opened 9 new positions and closed 8 in Q2 2025.
- Prosight Management's portfolio value rose 35% quarter-over-quarter to $410M.
Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.